Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials

BACKGROUND: With the appearance of oral direct-acting antivirals (DAAs), the field of hepatitis C virus (HCV) treatment has been dramatically changed. This evolution makes possible for all oral treatments to be available for the treatment of HCV-infected patients. The aims of this review were to rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Young-Mo, Choi, Eun Joo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395279/
https://www.ncbi.nlm.nih.gov/pubmed/28442915
http://dx.doi.org/10.2147/TCRM.S134818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395279/
https://www.ncbi.nlm.nih.gov/pubmed/28442915
http://dx.doi.org/10.2147/TCRM.S134818

Ejemplares similares